Simulated Pediatric Blood Cultures to Assess the Inactivation of Clinically Relevant Antimicrobial Drug Concentrations in Resin-Containing Bottles

Liliana Giordano1,2†, Flora Marzia Liotti1,2†, Giulia Menchinelli1,2†, Giulia De Angelis1,2, Tiziana D’Inzeo1,2, Grazia Angela Morandotti2, Maurizio Sanguinetti1,2*, Teresa Spanu1,2 and Brunella Posteraro1,3

1 Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy, 2 Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Poliambulanza Universitario A. Gemelli IRCCS, Rome, Italy, 3 Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Poliambulanza Universitario A. Gemelli IRCCS, Rome, Italy

*Correspondence: Maurizio Sanguinetti, maurizio.sanguinetti@unicatt.it
†These authors have contributed equally to this work

Specialty section: This article was submitted to Clinical Microbiology, a section of the journal Frontiers in Cellular and Infection Microbiology

Received: 12 January 2021
Accepted: 01 March 2021
Published: 19 March 2021

Citation: Giordano L, Liotti FM, Menchinelli G, De Angelis G, D’Inzeo T, Morandotti GA, Sanguinetti M, Spanu T and Posteraro B (2021) Simulated Pediatric Blood Cultures to Assess the Inactivation of Clinically Relevant Antimicrobial Drug Concentrations in Resin-Containing Bottles. Front. Cell. Infect. Microbiol. 11:649769. doi: 10.3389/fcimb.2021.649769

The bacteremia level as well as the administration of antibiotics before blood collection may significantly affect the recovery of bacterial pathogens from pediatric blood cultures in BacT/Alert Virtuo or Bactec FX BC systems, which remain the common techniques to diagnose bacteremia in pediatric patients. We simulated pediatric blood cultures with low or intermediate bacteremia level to evaluate BacT/Alert PF Plus and Bactec Peds Plus blood culture bottles for resin-based inactivation of 16 antibiotic–bacterium combinations. Overall, 105/192 (54.7%) of BacT/Alert PF Plus bottles and 69/192 (36.0%) of Bactec Peds Plus bottles allowed organisms to grow when exposed to antibiotics. In particular, both BacT/Alert PF Plus and Bactec Peds Plus bottles proved to be effective with piperacillin/tazobactam and Pseudomonas aeruginosa or with oxacillin and methicillin-susceptible Staphylococcus aureus (100% growth), whereas no effectiveness was apparent with ceftriaxone and Escherichia coli, Streptococcus agalactiae, or Streptococcus pneumoniae or with cefepime and E. coli (0% growth). In some relevant instances (e.g., with vancomycin and methicillin-resistant S. aureus or Streptococcus pneumoniae), BacT/Alert PF Plus bottles were superior to Bactec Peds Plus bottles. Together, these findings underscore the potentiality of resin-containing bottles to enhance diagnosis of bacteremia in pediatric patients on antimicrobial therapy. This is particularly true with one of the evaluated BC systems and with simulated intermediate bacteremia level only.

Keywords: bacteremia, antimicrobial drugs, simulated blood cultures, pediatric patients, therapeutic drug concentrations
INTRODUCTION

Bloodstream infection (BSI) remains a major cause of morbidity and mortality in pediatric patients (Weiss et al., 2015), especially in neonates (Shane et al., 2017) and hematology/oncology patients (Dandoy et al., 2019). Like in adult populations, blood culture (BC) coupled with antibiotic administration (Liu et al., 2017), BC may allow for cessation of unnecessary empirical antimicrobial therapy in case of negative results (Dien Bard and McElvania TeKippe, 2016). Besides being a prerequisite for targeted antibiotic administration (Li et al., 2017), BC may allow for cessation of unnecessary empirical antimicrobial therapy in case of negative results (Wilson, 2020a). Besides being a prerequisite for targeted antibiotic administration (Li et al., 2017), BC may allow for cessation of unnecessary empirical antimicrobial therapy in case of negative results (Wilson, 2020a). Besides being a prerequisite for targeted antibiotic administration (Li et al., 2017), BC may allow for cessation of unnecessary empirical antimicrobial therapy in case of negative results (Wilson, 2020a). Besides being a prerequisite for targeted antibiotic administration (Li et al., 2017), BC may allow for cessation of unnecessary empirical antimicrobial therapy in case of negative results (Wilson, 2020a).

A technological advance to optimize BC performance (Wilson, 2020b) is the introduction of specialized “Plus” BC bottles that contain antibiotic binding resins (Flayhart et al., 2007; Roh et al., 2012; Chung et al., 2019; Menchinelli et al., 2019a; Menchinelli et al., 2019b; Xu et al., 2021). In previous formulations, pediatric BC bottles marketed by bioMérieux—namely BacT/Alert Pediatric FAN (PF) BC bottles—contained 8.5% charcoal suspension as an antibiotic-neutralizing (or inactivating) substance. The only recently published bacteremia simulating study in the pediatric setting (Dien Bard and McElvania TeKippe, 2016) has compared BacT/Alert PF (bioMérieux) and Bactec Peds Plus (Becton Dickinson) BC bottles for their efficacy against eight organism-appropriate antibiotics (Sullivan et al., 2013). Consistently, studies investigating the effect of antibiotic-inactivating substances using the newer BacT/Alert PF Plus BC bottle are lacking.

The aim of this study was to evaluate both BacT/Alert PF Plus and Bactec Peds Plus bottles for the in vitro inactivation of clinically relevant antimicrobial drug concentrations using a pediatric BC simulation model. We tested different antibiotic-organism combinations in BC bottles inoculated with 2 ml human blood, which was consistent with a BC system manufacturers’ validated 1–4 ml optimum to detect BSI pathogens (Huber et al., 2020).

Part of these results would have been presented as an Abstract at the 30th European Congress of Clinical Microbiology and Infectious Diseases that would have taken place in Paris, France, 2020, but which was cancelled.

MATERIALS AND METHODS

Study Design, Organisms, and Simulated Cultures

In this BC simulation study, eight aerobic or facultative anaerobic organisms (Escherichia coli ATCC® 25922™, Pseudomonas aeruginosa ATCC® 27853™, methicillin-resistant Staphylococcus aureus [MRSA] ATCC® 43300™, methicillin-susceptible Staphylococcus aureus [MSSA] ATCC® 29213™, Staphylococcus capitis ATCC® 146™, Staphylococcus epidermidis ATCC® 12228™, Streptococcus agalactiae ATCC® 12386™, and Streptococcus pneumoniae ATCC® 49619™) were used. Bacteria were suspended in phosphate-buffered saline to achieve a McFarland density of 0.5 (equivalent to ~1 × 10⁸ CFU/ml). After three successive 100-fold dilutions, two aliquots of bacterial suspension, one containing ~10 CFU/ml and the other one containing ~60 CFU/ml were prepared. Then, 0.5 ml from each aliquot was inoculated into BacT/Alert PF Plus or Bactec Peds Plus bottle with 2 ml of banked human whole blood (obtained from the Division of Transfusion Medicine of our institution). This allowed simulating, for each series of bottles, bacteremia levels of 2–3 CFU (low) or 14–16 CFU (intermediate) per ml of blood, respectively. We defined as low or intermediate those levels that, albeit at a different extent, were considerably below the 50 CFU per ml of blood reported to be high level in children (Kellogg et al., 2000). Despite being arbitrary, this categorization was reflective of bacteremia levels frequently encountered in pediatric patients (Dien Bard and McElvania TeKippe, 2016). Because the volume of growth medium was 30 ml in the BacT/Alert PF Plus bottle and 40 ml in the Bactec Peds Plus bottle, final CFU numbers per bottle dropped proportionally. In each experiment day, the inoculum size was confirmed by plating each organism’s suspension on standard solid media. Based on relevance (Amsden, 2010; Sullivan et al., 2013), we chose eight antimicrobial drugs (ampicillin, cefepime, ceftriaxone, gentamicin, meropenem, oxacillin, piperacillin-tazobactam, and vancomycin) as representative of commonly used antibiotics for the empirical antimicrobial therapy of suspected BSIs at our institution’s pediatrics clinic. We purchased ampicillin, ceftriaxone, and vancomycin from Sigma-Aldrich (Saint Louis, MO, USA), cefepime, meropenem, and oxacillin from U.S. Pharmacopeia (Rockville, MD, USA), gentamicin and tazobactam from TOKU-E (Bellingham, WA, USA), and piperacillin from MP Biomedicals (Solon, OH, USA). Based on their MICs (Table 1, footnote b), all bacterial organisms displayed full susceptibility to the drugs specifically tested against them (ISO, 2006; CLSI, 2020). For each antimicrobial drug, a four-fold stock solution was prepared and diluted to reach final (peak or trough) concentrations (Table 1). For each antibiotic, concentrations were equal to the estimated therapeutic levels (Amsden, 2010; Sullivan et al., 2013) and were above the corresponding MIC value determined for each bacterial organism (Table 1, footnote b). Finally, BacT/Alert PF Plus or Bactec Peds Plus bottles were inoculated with 2 ml of blood, followed by 0.5 ml of the antibiotic suspension and 0.5 ml of the organism suspension (both prepared as described...
TABLE 1 | Detection results of organisms in resin-containing BacT/Alert or Bactec pediatric blood culture bottles according to antimicrobial drug and relative concentration.a

| Organisms in the presence of indicated drugs | Peak (P) or trough (T) drug concentration (µg/ml)b | Recovery by no. replicates/total (mean TTD [h]) for: BacT/Alert PF Plus bottles at a simulated bacteremia level of: 2–3 CFU/ml 14–16 CFU/ml 2–3 CFU/ml 14–16 CFU/ml | Recovery by no. replicates/total (mean TTD [h]) for: Bactec Peds Plus bottles at a simulated bacteremia level of: 2–3 CFU/ml 14–16 CFU/ml 2–3 CFU/ml 14–16 CFU/ml |
|-----------------------------------------------|-------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| **Escherichia coli**                          |                                                 |                                                                  |                                                                  |
| Cefepime                                      | P (164)                                         | 0/3 0/3 NA NA                                                   | 0/3 0/3 NA NA                                                   |
|                                               | T (10)                                          | 0/3 0/3 NA NA                                                  | 0/3 0/3 NA NA                                                  |
|                                               | No drug                                         | 3/3 (10.90) 3/3 (9.35)                                         | 3/3 (11.97) 3/3 (10.72)                                         |
| Ceftriaxone                                   | P (250)                                         | 0/3 0/3 NA NA                                                   | 0/3 0/3 NA NA                                                   |
|                                               | T (94)                                          | 0/3 0/3 NA NA                                                  | 0/3 0/3 NA NA                                                  |
|                                               | No drug                                         | 3/3 (10.03) 3/3 (10.01)                                        | 3/3 (11.97) 3/3 (10.42)                                        |
| Meropenem                                     | P (58.5)                                        | 0/3 0/3 NA NA                                                   | 0/3 0/3 NA NA                                                   |
|                                               | T (0.2)                                         | 0/3 0/3 (14.49) NA                                            | 0/3 0/3 (19.43) NA                                            |
|                                               | No drug                                         | 3/3 (12.91) 3/3 (10.71)                                        | 3/3 (15.62) 3/3 (11.68)                                        |
| Pseudomonas aeruginosa                       |                                                |                                                                  |                                                                  |
| Cefepime                                      | P (164)                                         | 0/3 3/3 (26.25) NA                                            | 0/3 0/3 NA NA                                                   |
|                                               | T (10)                                          | 3/3 (15.31) 3/3 (15.05)                                        | 3/3 (17.40) 3/3 (15.08)                                        |
|                                               | No drug                                         | 3/3 (15.05) 3/3 (14.46)                                        | 3/3 (17.20) 3/3 (15.08)                                        |
| Gentamicin                                    | P (8)                                           | 0/3 0/3 (15.05) NA                                            | 0/3 0/3 (15.58) NA                                            |
|                                               | T (1)                                           | 3/3 (15.31) 3/3 (15.12)                                        | 3/3 (17.4) 3/3 (15.08)                                         |
|                                               | No drug                                         | 3/3 (15.33) 3/3 (14.46)                                        | 3/3 (17.12) 3/3 (15.28)                                        |
| Meropenem                                     | P (58.5)                                        | 0/3 0/3 NA NA                                                   | 0/3 0/3 NA NA                                                   |
|                                               | T (0.2)                                         | 0/3 0/3 (13.22) NA                                            | 0/3 0/3 (17.40) NA                                            |
|                                               | No drug                                         | 3/3 (12.12) 3/3 (13.11)                                        | 3/3 (17.34) 3/3 (14.06)                                        |
| Piperacillin-tazobactam                      | P (240/24)                                      | 3/3 (16.11) 3/3 (14.49)                                        | 3/3 (17.58) 3/3 (16.10)                                        |
|                                               | T (5/0.7)                                       | 3/3 (15.53) 3/3 (14.12)                                        | 3/3 (17.58) 3/3 (16.22)                                        |
|                                               | No drug                                         | 3/3 (14.12) 3/3 (13.11)                                        | 3/3 (16.34) 3/3 (15.08)                                        |
| Methicillin-resistant Staphylococcus aureus   |                                                |                                                                  |                                                                  |
| Vancomycin                                    | P (50)                                          | 3/3 (15.00) 3/3 (13.54)                                        | 0/3 0/3 (16.54) NA                                            |
|                                               | T (10)                                          | 3/3 (14.59) 3/3 (13.20)                                        | 0/3 0/3 (17.59) 3/3 (15.20)                                    |
|                                               | No drug                                         | 3/3 (10.17) 3/3 (8.67)                                         | 3/3 (11.19) 3/3 (10.22)                                        |
| Methicillin-susceptible Staphylococcus aureus |                                                |                                                                  |                                                                  |
| Oxacillin                                     | P (230)                                         | 3/3 (11.56) 3/3 (9.89)                                         | 3/3 (15.62) 3/3 (15.29)                                        |
|                                               | T (15)                                          | 3/3 (11.55) 3/3 (10.71)                                        | 3/3 (15.68) 3/3 (12.67)                                        |
|                                               | No drug                                         | 3/3 (11.26) 3/3 (9.89)                                         | 3/3 (15.54) 3/3 (10.93)                                        |
| Vancomycin                                    | P (50)                                          | 0/3 0/3 (15.07) NA                                            | 0/3 0/3 (21.27) NA                                            |
|                                               | T (10)                                          | 3/3 (16.22) 3/3 (13.43)                                        | 0/3 0/3 (17.02) NA                                            |
|                                               | No drug                                         | 3/3 (11.26) 3/3 (11.13)                                        | 3/3 (15.54) 3/3 (10.92)                                        |
| Staphylococcus capitis                        |                                                |                                                                  |                                                                  |
| Vancomycin                                    | P (50)                                          | 0/3 0/3 (17.54) NA                                            | 0/3 0/3 (18.23) NA                                            |
|                                               | T (10)                                          | 3/3 (18.35) 3/3 (16.59)                                        | 0/3 0/3 (17.59) NA                                            |
|                                               | No drug                                         | 3/3 (15.11) 3/3 (14.11)                                        | 3/3 (16.12) 3/3 (15.53)                                        |
| Staphylococcus epidermidis                    |                                                |                                                                  |                                                                  |
| Vancomycin                                    | P (50)                                          | 0/3 0/3 (17.32) NA                                            | 0/3 0/3 (18.23) NA                                            |
|                                               | T (10)                                          | 3/3 (18.23) 3/3 (16.39)                                        | 0/3 0/3 (17.59) NA                                            |
|                                               | No drug                                         | 3/3 (15.33) 3/3 (14.10)                                        | 3/3 (16.12) 3/3 (15.53)                                        |
| Streptococcus agalactiae                     |                                                |                                                                  |                                                                  |
| Ampicillin                                    | P (47)                                          | 3/3 (12.13) 3/3 (11.20)                                        | 0/3 0/3 (13.49) 3/3 (12.33)                                    |
|                                               | T (3)                                           | 3/3 (10.47) 3/3 (10.38)                                        | 3/3 (10.19) 3/3 (9.12)                                         |
|                                               | No drug                                         | 3/3 (9.12) 3/3 (8.12)                                          | 3/3 (10.19) 3/3 (9.12)                                         |
| Ceftriaxone                                   | P (250)                                         | 0/3 0/3 NA NA                                                  | 0/3 0/3 NA NA                                                  |
|                                               | T (94)                                          | 0/3 0/3 NA NA                                                  | 0/3 0/3 NA NA                                                  |
|                                               | No drug                                         | 3/3 (9.22) 3/3 (8.31)                                          | 3/3 (10.11) 3/3 (9.32)                                         |
| Streptococcus pneumoniae                     |                                                |                                                                  |                                                                  |
| Ceftriaxone                                   | P (250)                                         | 0/3 0/3 NA NA                                                  | 0/3 0/3 NA NA                                                  |
|                                               | T (94)                                          | 0/3 0/3 NA NA                                                  | 0/3 0/3 NA NA                                                  |
|                                               | No drug                                         | 3/3 (13.65) 3/3 (13.32)                                        | 3/3 (15.05) 3/3 (14.82)                                        |

(Continued)
### TABLE 1 | Continued

| Organisms in the presence of indicated drugs | Peak (P) or trough (T) drug concentration (µg/ml)* | Recovery by no. replicates/total (mean) TTD [h] for: | ∆TTD (h) for: |
|---------------------------------------------|-----------------------------------------------|-----------------------------------------------|---------------|
|                                             | BacT/Alert PF Plus bottles at a simulated bacteremia level of: | BacTec Peds Plus bottles at a simulated bacteremia level of: |
|                                             | 2–3 CFU/ml | 14–16 CFU/ml | 2–3 CFU/ml | 14–16 CFU/ml | 2–3 CFU/ml | 14–16 CFU/ml | 2–3 CFU/ml | 14–16 CFU/ml |

**Note:** ∆TTD = TTD (h) for Bactec Peds Plus bottles – TTD (h) for BacT/Alert PF Plus bottles.

*Mean time to detection (TTD) was calculated on three replicates of simulated blood cultures for each of listed organism–antimicrobial drug combinations; ∆TTD was calculated by difference of the mean TTD of bottles with any antimicrobial drug concentration and the mean TTD of bottles (controls) without antimicrobial drug; NA, not applicable.

*For each antimicrobial drug tested, P or T concentrations were equal to the estimated therapeutic levels reported elsewhere ([Arrand et al., 2019; Sullivan et al., 2019], and were above the MIC values for listed bacterial organisms as reported in the documents by EUCAST ([http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf)) or, only for ceftriaxone and S. agalactiae, CLSI (2020). For ampicillin, MIC value was 0.06 (S. agalactiae); for cefepime, MIC values were 0.06 µg/ml (E. coli) and 2 µg/ml (P. aeruginosa); for ceftriaxone, MIC values were 0.06 µg/ml (E. coli) and 0.25 µg/ml (S. agalactiae), and 0.06 µg/ml (S. pneumoniae); for gentamicin, MIC value was 2 µg/ml (P. aeruginosa); for meropenem, MIC values were 0.06 µg/ml (E. coli) and 0.12 µg/ml (P. aeruginosa); for oxacillin, MIC value was 0.12 µg/ml (methicillin-resistant S. aureus), methicillin-susceptible S. aureus, S. capitis, or S. epidermidis) and 0.25 µg/ml (S. pneumoniae), respectively.

above). Bottles containing antibiotic-free whole blood were or not inoculated with bacterial organisms and were included as controls.

In total, we tested in triplicate antibiotic–organism combinations with their respective controls at each of two bacteremia levels. Shortly after inoculation, BacT/Alert PF Plus or Bactec Peds Plus bottles were loaded into the respective BacT/Alert Virtuo or Bactec FX BC instruments, and then incubated for a maximum of 5 days (120 h) or until growth was detected. A positive signal (growth detection) within 120 h was used as the endpoint to calculate the time to detection (TTD) for each bottle (i.e., the time from the bottle loading into the instrument to a positive signal). Bottles that remained negative at 120 h were recorded as “no growth”. Standard subcultures from any BC bottle were performed to confirm positive or negative detection results and/or to exclude possible contaminations.

### Data Analysis

Results were reported as percentages of recovered organisms or as mean TTDs in each BC system, and differences between results in predefined groups were assessed using the Mc Nemar’s test or the paired t test, as appropriate. Statistical analyses were performed using the Intercooled Stata program version 11 and GraphPad Prism 7, and a P value of <0.05 was considered statistically significant.

### RESULTS

Among 576 simulated BacT/Alert PF Plus or Bactec Peds Plus BC bottles, 384 bottles were tested with bacterial organisms in the presence of clinically relevant peak (192 bottles) or trough (192 bottles) antibiotics’ concentrations, whereas 192 bottles (controls) were tested in the absence of antibiotics. As expected, 100% (192/192) of controls yielded all the organisms included in the study. Conversely, growth was detected in 105/192 (54.7%) of BacT/Alert PF Plus bottles and in 69/192 (36.0%) of Bactec Peds Plus bottles with organisms exposed to antibiotics. As shown in Figure 1A, percentages of organism recovery between bottles (BacT/Alert PF Plus versus Bactec Peds Plus) were significantly different when stratifying results by antimicrobial drug peak [43.8% (42/96) versus 18.8% (18/96), P <0.0001] or trough [65.6% (63/96) versus 53.1% (51/96), P = 0.0005] concentrations. Similarly (Figure 1B), significant differences were seen in the percentage of organism recovery when stratifying results by simulated bacteremia low [40.6% (39/96) versus 25.0% (24/96), P = 0.0001] or intermediate [68.8% (66/96) versus 46.9% (45/96), P <0.0001] levels. Excluding ceftriaxone—no organisms were recovered when exposed to this drug (Table 1)—recovery results in BacT/Alert PF Plus versus Bactec Peds Plus bottles were shown by thirteen antibiotic–organism combinations (Figure 1C). Thus, percentages of S. agalactiae recovery in the presence of ampicillin differed significantly [100% (12/12) versus 50.0% (6/12), P = 0.01] as well as those for all species [75.0% (45/60) versus 35.0% (21/60), P <0.0001], S. capsitis [75.0% (9/12) versus 25.0% (3/12), P = 0.01], S. epidermidis [75.0% (9/12) versus 25.0% (3/12), P = 0.01], or S. pneumoniae [50.0% (6/12) versus 0.0% (0/12), P = 0.01], respectively, exposed to vancomycin (Figure 1C).

As shown in Table 1, the BacT/Alert PF Plus bottles allowed organism recovery in drug concentrations that Bactec Peds bottles did not. Some bottles (simulating low-level bacteremia with the indicated organism) contained vancomycin peak (MRSA), vancomycin trough (MSSA, S. capitis, or S. epidermidis), or ampicillin peak (S. agalactiae) concentrations. The remaining bottles (simulating intermediate-level bacteremia with the indicated organism) contained cefepime peak (P. aeruginosa), ampicillin peak (S. agalactiae), vancomycin peak (S. capitis, S. epidermidis, or S. pneumoniae), or vancomycin trough (S. pneumoniae) concentrations. In both BacT/Alert PF Plus and Bactec Peds Plus bottles, drugs inhibited growth of E. coli (cefepime and ceftriaxone) and of S. agalactiae and S. pneumoniae (ceftriaxone), whereas meropenem inhibited growth of E. coli and
P. aeruginosa only in low-level bacteremia simulating bottles. Of note, the two organisms were shown to overcome the meropenem inhibition in intermediate-level bacteremia simulating bottles. Conversely, both BacT/Alert PF Plus and Bactec Peds Plus bottles allowed P. aeruginosa and MSSA to grow in the presence of piperacillin/tazobactam or oxacillin, respectively. Overall, the mean TTD was 14.71 h (range, 9.89 to 26.25 h) with the BacT/Alert PF Plus bottle and 16.37 h (range, 12.33 to 21.27 h) with the Bactec Peds Plus bottle ($P = 0.04$). As expected, ΔTTDs ≥3 h between bottles with drug and the paired controls (no-drug bottles) were observed with either BacT/Alert PF Plus or Bactec Peds Plus bottles whereas, in some cases, both bottle types had extended ΔTTD. These included vancomycin peak (intermediate-level MRSA or MSSA bacteremia) and trough (low/intermediate-level MRSA bacteremia).

**FIGURE 1** | Percentages of organism recovery from BacT/Alert PF Plus or Bactec Peds Plus BC bottles inoculated with antibiotic-containing blood as stratified by antibiotics peak or trough concentrations (A), low or intermediate bacteremia levels (B), and antibiotic–organism combinations (C), respectively. Percentages are relative to the organism recovery from the total of antibiotic-containing BC bottles inoculated for each indicated group. All (100%) of BC bottles without antibiotics used as controls yielded organism recovery (data not shown). Asterisks indicate the statistical significance of comparisons between BC bottles ($^*P < 0.01$; $^{**}P < 0.001$; $^{***}P < 0.0001$). Comparisons with $P$ values of >0.05 were not indicated.
bacteremia) concentrations or trough meropenem (intermediate-level *E. coli* bacteremia) concentration.

**DISCUSSION**

Our findings add to the information recently published on resin-containing bottles BacT/Alert Plus and Bactec Plus in simulated BCs. These so called "Plus" bottle formulations are able to support and/or enhance the growth of several pathogens commonly isolated from blood (Wilson, 2020b). In simulated low (2–3 CFU/ml) or intermediate (14–16 CFU/ml) bacteremia levels, BacT/Alert PF Plus or Bactec Peds Plus bottles recovered all bacterial species (*E. coli*, *P. aeruginosa*, four staphylococcal species, and two streptococcal species) in the absence of antimicrobial drugs (192 of 192 bottles). BacT/Alert PF Plus or Bactec Peds Plus bottles led to satisfactory organisms’ recovery rates when inoculated with bacterial species and antimicrobial drugs to which they were susceptible. This was because of resins’ binding kinetics that was capable to quickly lower drug concentrations to below organisms’ MICs.

To the best of our knowledge, this is the first study to evaluate BacT/Alert PF Plus bottles after 2013, the year these bottles became commercially available. Indeed, published studies until now (Chen et al., 2019; Chung et al., 2019; Menchinelli et al., 2019b; Xu et al., 2021) have simulated adult BCs—using human, horse, or sheep blood sources—to assess the antibiotic inactivation capability of Bactec Plus Aerobic/F or Anaerobic/F bottles in comparison with BacT/Alert FA Plus (aerobic) or FN Plus (anaerobic) bottles. In our study, both BacT/Alert PF Plus and Bactec Peds Plus bottles showed 100% recovery in two instances (piperacillin/tazobactam with *P. aeruginosa* and oxacillin with MSSA), which suggests that antibiotic-binding resins might be effective regardless of bacteria or antibiotic levels in blood samples. In other instances, both BacT/Alert PF Plus and Bactec Peds Plus bottles showed 0% recovery (ceftriaxone with *E. coli*, *S. agalactiae*, or *S. pneumoniae*, and cefepime with *E. coli*) or partial recovery (meropenem with *E. coli* or *P. aeruginosa*). These findings are similar to those by Sullivan et al. (2013), who reported no recoveries for not only *E. coli*, *S. agalactiae*, or *S. pneumoniae* but also for *Neisseria meningitidis* or *Haemophilus influenzae* (two fastidious organisms responsible for pediatric BSI) when tested in the presence of third-generation cephalosporins (ceftriaxone or cefotaxime). Similarly, our previous study (albeit in the adult setting) showed no recovery for *E. coli* when tested in the presence of meropenem at the lowest but clinically relevant concentration in both BacT/Alert (FA Plus and FN Plus) and Bactec (Plus Aerobic/F and Plus Anaerobic/F) bottles (Menchinelli et al., 2019b). Concomitantly, Chen et al. (2019) showed that the recovery of *E. coli* exposed to meropenem midpoint and trough concentrations was more successful in BacT/Alert FN Plus bottles than in Bactec Plus Anaerobic/F bottles. However, it should be noted that the bacterial inoculum (50 to 100 CFU per bottle) used by Menchinelli et al. (2019b) was much higher than the inoculum (7 to 30 CFU per bottle) used by Chen et al. (2019), and this difference might have caused the dissimilar performance of BC bottles observed in the two studies.

Overall, compared to adult counterparts (Chen et al., 2019; Menchinelli et al., 2019b), pediatric BC bottles displayed lower recovery rates, particularly at peak drug concentrations or low bacteremia levels tested. This was despite the broth-to-blood ratio in adult bottles being equivalent to that in pediatric bottles, implying that no dilution effect might have caused the above contrasting observations.

We noticed striking superiority of the BacT/Alert PF Plus bottle with ampicillin or cephalosporin peak concentrations and with vancomycin peak and trough concentrations. Instead, the Bactec Peds Plus bottle failed to prevent the antibiotic-mediated inhibition of growth for the organism exposed to these drugs. Conversely, Sullivan et al. (2013) noticed that the Bactec Peds Plus bottle was able to recover *Staphylococcus* spp. (MRSA and *S. epidermidis*) or *S. pneumoniae* organisms when exposed to vancomycin peak and trough concentrations. A reason for contrasting results between the studies may be the difference in the simulated level of bacteremia, namely 10 to 100 CFU/ml (Sullivan et al., 2013) or 2 to 16 CFU/ml (present study). Interestingly, we noticed that BacT/Alert PF Plus bottles also had significantly shorter TTD in both control (inoculated with antibiotic-free blood) and test (inoculated with antibiotic-containing blood) bottles. It is plausible that BacT/Alert PF Plus bottles are more enriched in some component(s) than Bactec Peds Plus bottles that may accelerate organisms’ growth. Taken together, these observations underscore the possibility for more rapid detection of BSI pathogens (Spaulding et al., 2019) using the BacT/Alert PF Plus bottles. The study further underscores the need for more caution with the timing of blood collection in patients at risk of *Staphylococcus* spp. or *S. pneumoniae* bacteremia when using the Bactec Peds Plus bottles.

The strength of this study includes the simulation of pediatric bacteremia at low or intermediate levels, mimicking the common scenario of levels in pediatric BC bottles inoculated with 2-ml blood volume. Although bacteremia is a difficult clinical entity to classify as low, intermediate (or moderate), or high, we are confident that the two experimentally made levels do actually correspond to clinical situations that may differently affect pediatric management and outcomes (Kellogg et al., 2000). We did not simulate a high bacteremia level because it seemed to represent a less common situation (Dien Bard and McElvania TeKippe, 2016). Meanwhile, our experimental design did not hamper us comparing detection (and relative TTD) in the control versus test bottles. One limitation of this study is the use of seeded banked whole blood (*i.e.*, obtained from adult donors) to simulate actual clinical samples. In this context, we acknowledged the potential inhibitory effect of adult blood because of antibodies or activation complement components, which may affect bacterial growth or may clear organisms even in the absence of antibiotics. Instead, use of clinical samples would take into account the interference by molecules involved in the bacteremia process or by antibiotics administered before sampling. Secondly, we did not determine antibiotic concentrations in test bottles at the initial and subsequent time points of inoculation to ensure consistency between the observed whole-blood concentrations and the predicted peak or trough
concentrations for antibiotics used. Additionally, organisms allowed to grow in bottles containing trough antibiotic concentrations were never exposed to peak antibiotic concentrations. This would hinder assessing the post-antibiotic effect or the ratio of the area under the concentration–time curve (AUC) to the MIC, which underlies antibiotics’ exposure-to-effect relationships. Thirdly, the number of bacterial pathogens included in our study was limited, thereby excluding fastidious organisms like *N. meningitidis* or *H. influenzae*. To date, it is unknown about further BC bottles’ advances to enhance the recovery of difficult-to-grow but clinically important organisms. Fourthly, the number of replicates for each antibiotic combination in our study could be enlarged.

In conclusion, resin-based antibiotic inactivation in BacT/Alert PF Plus bottles may be superior to in Bactec Peds Plus bottles when simulating low/intermediate bacteremia in pediatric patients on antimicrobial therapy. For both BacT/Alert Plus and Bactec Peds Plus bottles, performance was optimal with either piperacillin/tazobactam (i.e., first-line antibiotic in *P. aeruginosa* bacteremia) or oxacillin (i.e., first-line antibiotic in MSSA bacteremia). However, performance of both bottles was far from optimal with either ceftriaxone (i.e., first-line antibiotic in *E. coli*, *S. agalactiae*, or *S. pneumoniae* bacteremia) or cefepime (i.e., first-line antibiotic in *E. coli* bacteremia). Further studies will allow full appreciation of the advantages of BacT/Alert PF Plus or Bactec Peds Plus BC bottles in patients for whom empirically administered antimicrobials prior to BC sampling make detection of bacteremia particularly difficult.

**REFERENCES**

Amsden, G. W. (2010). “Tables of antimicrobial agent pharmacology,” in *Principles and practice of infectious diseases*, 7th ed, vol. 1. Eds: G. L. Mandell, J. E. Bennett and R. Dolin (Philadelphia, PA: Churchill Livingstone Elsevier), p 765–p 761. doi: 10.1016/B978-0-443-06839-3.00049-7

Cecconi, M., Evans, L., Levy, M., and Rhodes, A. (2018). Sepsis and septic shock. *Lancet* 392, 75–87. doi: 10.1016/S0140-6736(18)30696-2

Chen, I. H., Nicolau, D. P., and Kuti, J. L. (2019). Effect of clinically meaningful antibiotic concentrations on recovery of *Escherichia coli* and *Klebsiella pneumoniae* isolates from anaerobic blood culture bottles with and without antibiotic binding resins. *J. Clin. Microbiol.* 57, e01344–e01319. doi: 10.1128/JCM.01344-19

Chung, Y., Kim, I. H., Han, M., Kim, H. S., Kim, H. S., Song, W., et al. (2019). A comparative evaluation of BACT/ALERT FA PLUS and FN PLUS blood culture bottles and BD BACTEC Plus Aerobic and Anaerobic blood culture bottles for antimicrobial neutralization. *Eur. J. Clin. Microbiol. Infect. Dis.* 38, 2229–2233. doi: 10.1007/s10096-019-3666-3

CLSI (2020). *Performance standards for antimicrobial susceptibility testing. CLSI supplement M100* (Wayne, PA: Clinical and Laboratory Standards Institute).

Dandoy, C. E., Kelley, T., Gaur, A. H., Nagarajan, R., Demmel, K., Alonso, P. B., et al. (2019). Outcomes after bloodstream infection in hospitalized pediatric hematology/oncology and stem cell transplant patients. *Pediatr. Blood Cancer* 66, e27978. doi: 10.1002/bpc.27978

Dien Bard, J., and McElvania TeKippe, E. (2016). Diagnosis of bloodstream infections in children. *J. Clin. Microbiol.* 54, 1418–1424. doi: 10.1128/JCM.02919-15

Flayhart, D., Bezek, A. P., Wakefield, T., Dick, J., and Carroll, K. C. (2007). Comparison of BACTEC PLUS blood culture media to BacT/Alert FA blood culture media for detection of bacterial pathogens in samples containing therapeutic levels of antibiotics. *J. Clin. Microbiol.* 45, 816–821. doi: 10.1128/JCM.02064-06

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**AUTHOR CONTRIBUTIONS**

LG, FML, and GM performed the experimental work and data analysis. GDA, TDI, and GAM helped analyze the data. MS, TS, and BP conceived the study and supervised the study conduction and the data analysis. BP wrote the paper. LG, FML, GM, and GDA helped write the paper. All authors contributed to the article and approved the submitted version.

**FUNDING**

BioMérieux provided reagents and funding for this study, participated in the study design, and critically reviewed the manuscript before submission.

**ACKNOWLEDGMENTS**

We wish to thank Franziska Lohmeyer for her English language assistance.

Huher, S., Heterz, B., Crazzolara, R., and Orth-Höller, D. (2020). The correct blood volume for paediatric blood cultures: a conundrum? *Clin. Microbiol. Infect.* 26, 168–173. doi: 10.1016/j.cmi.2019.10.006

ISO (2006). *Clinical laboratory testing and in vitro diagnostic test systems—susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices—Part 1: reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases* (Geneva, Switzerland: International Organization for Standardization), ISO 20776–1. Available at: http://www.eucast.org/ast_of_bacteria/mic_determination/.

Kellogg, J. A., Manzella, J. P., and Bankert, D. A. (2000). Frequency of low-level bacteremia in children from birth to fifteen years of age. *J. Clin. Microbiol.* 38, 2181–2185. doi: 10.1128/JCM.38.12.2181–2185.2000

Liu, V. X., Fielding-Singh, V., Greene, J. D., Baker, J. M., Iwashyna, T. J., Bhattacharya, J., et al. (2017). The timing of early antibiotics and hospital mortality in sepsis. *Am. J. Respir. Crit. Care Med.* 196, 856–863. doi: 10.1164/rccm.201609-1848OC

Menchinelli, G., Liotti, F. M., Fiori, B., De Angelis, G., D’Inzeo, T., Giordano, L., et al. (2019). In vitro evaluation of BACT/ALERT® VIRTUO®, BACT/ALERT 3D®, and BACTEC™ FX automated blood culture systems for detection of microbial pathogens using simulated human blood samples. *Front. Microbiol.* 10, 221. doi: 10.3389/fmicb.2019.00221

Menchinelli, G., Liotti, F. M., Giordano, L., De Angelis, G., Sanguinetti, M., Spanu, T., et al. (2019b). Efficient inactivation of clinically relevant antimicrobial drug concentrations by BacT/Alert or Bactec resin-containing media in simulated adult blood cultures. *Antimicrob. Agents Chemother.* 63, e00420–e00419. doi: 10.1128/AAC.00420-19

Roh, K. H., Kim, J. Y., Kim, H. N., Lee, H. J., Sohn, J. W., Kim, M. J., et al. (2012). Survival of *P. aeruginosa* bacterium allowed to grow in bottles containing trough antibiotic concentrations by BacT/Alert or Bactec resin-containing media in simulated in vitro activity of antimicrobial agents. *Front. Microbiol.* 3, 173. doi: 10.3389/fmicb.2012.00157

Theriault, P. H., Dragna, W., and Ahmad, I. (2013). Comparison of BACTEC® Plus aerobic and anaerobic blood culture bottles and BacT/Alert FAN aerobic and anaerobic blood culture bottles for the detection of bacteremia in ICU patients. *Diagn. Microbiol. Infect. Dis.* 73, 239–242. doi: 10.1016/j.diagmicrobio.2012.03.022
Shane, A. L., Sánchez, P. J., and Stoll, B. J. (2017). Neonatal sepsis. Lancet 390, 1770–1780. doi: 10.1016/S0140-6736(17)31002-4
Spaulding, A. B., Watson, D., Dreyfus, J., Heaton, P., Grapentine, S., Bendel-Stenzel, E., et al. (2019). Epidemiology of bloodstream infections in hospitalized children in the United States 2009–2016. Clin. Infect. Dis. 69, 995–1002. doi: 10.1093/cid/ciy1030
Sullivan, K. V., Turner, N. N., Lancaster, D. P., Shah, A. R., Chandler, L. J., Friedman, D. F., et al. (2013). Superior sensitivity and decreased time to detection with the Bactec Peds Plus/F system compared to the BacT/Alert Pediatric FAN blood culture system. J. Clin. Microbiol. 51, 4083–4086. doi: 10.1128/JCM.02205-13
Weiss, S. L., Fitzgerald, J. C., Pappachan, J., Wheeler, D., Jaramillo-Bustamante, J. C., Saloo, A., et al. (2015). Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am. J. Respir. Crit. Care Med. 191, 1147–1157. doi: 10.1164/rccm.201412-2323OC
Wilson, M. L. (2020a). Critical factors in the recovery of pathogenic microorganisms in blood. Clin. Microbiol. Infect. 26, 174–179. doi: 10.1016/j.cmi.2019.07.023
Wilson, M. L. (2020b). Development of new methods for detecting bloodstream pathogens. Clin. Microbiol. Infect. 26, 319–324. doi: 10.1016/j.cmi.2019.08.002
Xu, X., Wei, Q., Wang, Z., Yan, J., Wang, H., and Xia, Y. (2021). Inactivation of clinically frequently used antimicrobial agents by BacT/ALERT FAN Plus and BACTEC Aerobic and Anaerobic culture media in simulated blood cultures: first comparative evaluation in China Mainland. Infect. Drug Resist. 14, 163–172. doi: 10.2147/IDR.S290222
Zadroga, R., Williams, D. N., Gottschall, R., Hanson, K., Nordberg, V., Deike, M., et al. (2013). Comparison of 2 blood culture media shows significant differences in bacterial recovery for patients on antimicrobial therapy. Clin. Infect. Dis. 56, 790–797. doi: 10.1093/cid/cis1021
Conflict of Interest: The authors declare that bioMérieux provided reagents and funding for this study, participated in the study design, and critically reviewed the manuscript before submission.

Copyright © 2021 Giordano, Liotti, Menchinelli, De Angelis, D’Inzeo, Morandotti, Sanguinetti, Spanu and Posteraro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.